89Zr-Oxine Cell Labeling for Long-Term PET Tracking

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current preclinical imaging techniques for tracking cells, such as bioluminescence imaging and magnetic resonance imaging, are inadequate for clinical use due to limited sensitivity and specificity, and existing radiolabeling methods like 111In-oxine require high radiation doses and have short half-lives, making it difficult to track cells for several days without interfering with their survival or function.

Innovation Solution

A method is developed to prepare a 89Zr-oxine complex by combining oxine with 89ZrCl4 in hydrochloric acid, neutralizing the mixture, and optionally extracting it into an organic solvent, which is used to label cells for PET imaging, allowing tracking for several days without significantly affecting cell viability or function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If 111In-oxine radiolabeling is used to track cells, then cell tracking is enabled, but radiation dose to cells is high and tracking duration is limited due to short half-life

Engineering Contradiction:

Improvetracking durationVSAvoidradiation dose

Core Design Contradiction:

Duration of action of moving objectVSObject-affected harmful factors

Solution Approach 1:

The patent changes the radioactive isotope parameter from 111In (half-life 2.8 days) to 89Zr (half-life 78.4 hours), extending the tracking duration while reducing the radiation dose to cells by approximately one log, enabling long-term cell tracking with improved safety

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces the SPECT imaging system (used with 111In-oxine) with PET imaging system (used with 89Zr-oxine), achieving at least ten-fold higher sensitivity and resolution, which allows lower radiation doses to achieve the same imaging quality

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Measurement precision

If 18F-FDG is used to label cells, then PET imaging is achieved, but labeling relies on glucose metabolism making it unsuitable for dormant cells and 18F is released by phosphatase activity

Engineering Contradiction:

Improveimaging sensitivityVSAvoidlabel stability

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent introduces oxine (8-hydroxyquinoline) as an intermediary chelating agent that forms stable complexes with 89Zr, which are then taken up by cells. This intermediary approach avoids reliance on cellular metabolism (unlike 18F-FDG) and creates phosphatase-resistant labels, enabling stable long-term tracking of dormant and activated cells alike

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the radioactive isotope from 18F (half-life 109.7 min) to 89Zr (half-life 78.4 hours), extending the imaging window to several days and eliminating the phosphatase release issue that plagues 18F-FDG labeling

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If bioluminescence imaging is used to track cells, then cell tracking is possible, but light penetration in tissue is limited preventing whole body imaging

Engineering Contradiction:

Improveimaging capabilityVSAvoidimaging coverage

Core Design Contradiction:

Ease of operationVSArea of stationary object

Solution Approach 1:

The patent replaces bioluminescence/optical imaging with PET imaging using 89Zr-oxine, which uses penetrating gamma rays instead of visible light, enabling whole body imaging with high sensitivity and resolution without the tissue penetration limitations of optical methods

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

4Ease of operation

If magnetic resonance imaging with iron loaded cells is used, then cell tracking is achieved, but sensitivity is limited due to negative contrast on heterogeneous background

Engineering Contradiction:

Improveimaging capabilityVSAvoidimaging sensitivity

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent replaces MRI with PET imaging using 89Zr-oxine, achieving at least ten-fold higher sensitivity compared to MRI methods. The PET method provides positive contrast with no background radioactivity, eliminating the heterogeneous background problem that limits MRI sensitivity

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The 89Zr-oxine complex enables effective PET imaging of cells with high sensitivity and specificity, maintaining cell viability and function, and provides a safer, lower radiation dose alternative to existing methods, enabling long-term tracking of various cell types.

Implementation Method 1

combining a solution of oxine and 89ZrCl4 in hydrochloric acid to form a mixture, adding an alkaline solution to the mixture to neutralize the mixture, generating 89Zr-oxine complex

Methodology Applied

Scientific EffectChemical coordination: Chemical Bonding

Implementation Method 2

89Zr-oxine complex enables effective PET imaging of cells with high sensitivity and specificity

Methodology Applied

Scientific EffectRadioactive decay: Radioactive Decay

Data Source

PatentUS12473307B2Method of preparing zirconium-89 oxine complex

Publication Date: 2025.11.18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

AI summary

The invention provides a method of preparing a 89Zr-oxine complex of the formulaThe invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.